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Abstract
Axl receptor tyrosine kinase is involved in the growth and metastasis and is an indicator of poor prognosis in
several cancers including lung cancers. Although a mitogen-activated protein kinase (MAPK) pathway and an
epithelial-to-mesenchymal transition (EMT) program are critical, molecular mechanisms underlying the Axl-driven
cancer progression have not been fully elucidated. We aimed to identify molecules up-regulated by Axl kinase in
lung adenocarcinomas. Through the global gene expression analysis and the functional annotation clustering, we
found that AXL expression positively correlated with mRNA expressions of immune checkpoint molecules and
chemokine receptors in non-small-cell lung cancers. Validation cohorts including our biobank confirmed that the
AXL expression significantly correlated with expression of genes encoding programmed death-ligand1 (PD-L1) and
CXC chemokine receptor 6 (CXCR6) in lung adenocarcinoma, especially in epidermal growth factor receptor (EGFR)
mutation-positive adenocarcinoma. Pharmacological inhibition of Axl kinase activity decreased mRNA expressions of
PD-L1 and CXCR6 in EGFR mutation-positive cell lines. Our data indicates the novel role of Axl kinase as a driver of
immune checkpoint molecules and chemokine signalling pathways in the progression of lung adenocarcinomas.
This study also highlights the necessity of clinical trials in order to test the efficacy of Axl kinase inhibition in the
Axl-highly expressing subset of lung adenocarcinomas.
Keywords: Non-small-cell lung cancer, Axl receptor tyrosine kinase, Immune checkpoint molecules, Chemokine
signalling, Global gene expression array
Results and discussion
Gene signatures of NSCLC with higher AXL mRNA
expression
Activation of Axl receptor tyrosine kinase has a key role
in the growth and metastasis of several cancers [1]. In
lung adenocarcinomas, the protein expression of Axl and
its ligand, growth arrest specific-6 (Gas6), is a critical indi-
cator for the poor prognosis [2]. Moreover acquisition of
Axl leads to resistance to epidermal growth factor recep-
tor (EGFR)-targeted therapy for lung adenocarcinomas
[3]. Based on these studies, the combination therapy of a
selective Axl kinase inhibitor (BGB324) and an EGFR
tyrosine kinase inhibitor (Erlotinib) for patients with Stage
IIIB or IV non-small cell lung cancers (NSCLC) has cur-
rently been in a phase I/II clinical trial (NCT02424617).
Recent studies reported that intracellular kinases (e.g.
mitogen-activated protein kinases, MAPKs) and
epithelial-to-mesenchymal transition (EMT)-initiating tran-
scription factors are involved in the Axl-driven survival and
motility of cancers [1]. In addition a recent report indicates
that Axl also up-regulates the expression of an immune
checkpoint molecule, programmed death-ligand1 (PD-L1,
or CD274) in head and neck cancers [4]. These studies sug-
gest that the activation of Axl controls diverse molecular
pathways contributing to a microenvironment beneficial to
tumor progression. However the diverse array of molecules
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under Axl kinase has not been fully elucidated in lung
cancer.
In order to characterise molecular phenotypes of
NSCLC with higher AXL expression, we sought to identify
genes whose expressions significantly correlated with AXL
mRNA expression in a lung cancer tissue biobank (GSE
accession number, GSE42127, n = 176 subjects, Additional
file 1: Materials and Methods). In this discovery cohort,
we found that 935 genes positively correlated with AXL
expression (rp > 0.4; Additional file 2: Table S1), whereas
137 genes were negatively correlated (rp < − 0.4; Additional
file 2: Table S2). A functional annotation clustering
analysis revealed that gene ontology terms, “chemokine
mediated signalling pathway” and “antigen processing and
presentation”, were enriched in the 935 genes positively
correlating with AXL mRNA expression (Additional file 2:
Table S3). We failed to detect gene ontology terms in the
137 genes negatively correlating with AXL expression.
Positive correlation of AXL expression with immune
checkpoint molecules and chemokine receptors in lung
adenocarcinomas
Our unbiased analysis of the discovery cohort micro-
array data suggests that chemokine signalling pathways
Fig. 1 Genes encoding immune checkpoint molecules and chemokine/chemokine receptors were enriched in Axl-highly expressing NSCLC.
Correlations of mRNA expressions between AXL and genes encoding PD-L1 (CD274; a, g, m and s), PD-L2 (PDCD1LG2; b, h, n and t), CTLA-4
(CTLA4; c, i, o and u), CXCR4 (CXCR4; d, j, p and v), CXCR6 (CXCR6; e, k, q and w) and CXCL16 (CXCL16; f, l, r and x). Microarray data from three
cohorts (discovery cohort (a-f, GSE42127), validation cohort1 (g-l, GSE13213), validation cohort3 (s-x, TCGA Pan-Cancer Atlas) and qRT-PCR data
from our cohort of Tohoku University Biobank (m-r) are shown. rp is a Pearson correlation coefficient. The x-y axes indicate log2 transformed
expression values of genes indicated
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Fig. 2 (See legend on next page.)
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and molecules associated with antigen processing and
presentation (e.g., major histocompatibility complex
(MHC) genes) are relevant to de novo AXL-highly ex-
pressing NSCLC. A recent report indicated that genes
encoding MHC class I molecules positively correlated to
PD-L1 mRNA expression in ovarian tumor cells [5].
Thus we sought to further validate the contribution of
immune checkpoint molecules and chemokine signalling
pathways to Axl-expressing adenocarcinomas. We have
established Tohoku University Biobank (Additional file
2: Table S4). Using three independent validation cohorts
of lung adenocarcinomas (Validation cohort1: GSE13213
in the Gene Expression Omnibus (GEO) of the National
Center for Biotechnology Information (NCBI), n = 117;
Validation cohort2: Our cohort of Tohoku University
Biobank, n = 76; Validation cohort3: Lung Adenocarcin-
oma in The Cancer Genome Atlas (TCGA), Pan-Cancer
Atlas, n = 566), we found that AXL expression signifi-
cantly correlated with the expressions of genes encoding
immune checkpoint molecules (CD274, PDCD1LG2 and
CTLA4), chemokine receptors (CXCR4 and CXCR6) or a
chemokine (CXCL16) in the discovery cohort as well as
the three validation cohorts (Fig. 1). These chemokine
receptors have been attributed to the invasion and me-
tastases of cancers [6].
Higher expression of genes encoding PD-L1, CXCR6
and CXCL16 in Axl-expressing adenocarcinomas with
mutated EGFR.
To determine whether the EGFR mutation status is in-
fluential in the correlation of AXL expression with the
immune checkpoint molecules and the chemokine/che-
mokine receptors, we evaluated Pearson correlation coef-
ficients between EGFR mutation-positive and wild type
lung adenocarcinomas in our cohort of Tohoku Univer-
sity Biobank. We found higher correlations of gene ex-
pressions between AXL and three genes (CD274, CXCR6
and CXCL16) in EGFR-mutation positive adenocarcin-
omas than in wild type (Fig. 2).
(See figure on previous page.)
Fig. 2 Genes encoding PD-L1 and CXCR6 correlated with AXL mRNA in EGFR-mutated lung adenocarcinomas. Correlations of mRNA expressions
between AXL and genes encoding PD-L1 (CD274; a and g), PD-L2 (PDCD1LG2; b and h), CTLA-4 (CTLA4; c and i), CXCR4 (CXCR4; d and j), CXCR6
(CXCR6; e and k) and CXCL16 (CXCL16; f and l) in EGFR mutation-positive (a-f) and EGFR wild-type (l-l) lung adenocarcinomas from Tohoku
University Biobank. rp is a Pearson correlation coefficient. The x-y axes indicate log2 transformed expression values of genes indicated
Fig. 3 A selective inhibitor of Axl kinase decreased PD-L1, PD-L2 and CXCR6 mRNA expression in vitro. Relative expression values of CD274 (PD-
L1; a, d), PDCD1LG2 (PD-L2; b, e) and CXCR6 (c, f) in PC9 cells (a-c) and H1975 cells (d-f) six hours after treatment with 0.1% DMSO or Axl inhibitor
BGB324 (10 μM). Each value represents the fold-increase in gene expression of BGB324-treated cells compared to that of DMSO-treated cells in
each experiment. Data are expressed as the mean ± SD of three independent experiments. ****p < 0.0001, **p < 0.01, *p < 0.05, vs. DMSO; two-
tailed paired t-test. NS indicates not significant
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Pharmacological inhibition of Axl kinase activity
decreases the mRNA expressions of CD274, PDCD1LG2
and CXCR6 in EGFR mutation-positive lung
adenocarcinoma cell lines
To determine whether and how Axl regulates the mRNA
expressions of PD-L1, PD-L2 and CXCR6 in
EGFR-mutated lung adenocarcinomas, we treated two
EGFR mutation-positive lung adenocarcinoma cell lines
(PC9 cells and H1975 cells) with a selective Axl kinase
inhibitor BGB324 or with siRNA targeting Axl. We con-
firmed mRNA and protein expressions of Axl in both
PC9 cells and H1975 cells (data not shown) and verified
that the Axl inhibitor BGB324 decreased phosphoryl-
ation of Axl in these cell lines in a dose-dependent
manner (Additional file 3: Figure S1). We found that
BGB324 significantly decreased the expressions of
CD274 and PDCD1LG2 and CXCR6 in both cell lines
(Fig. 3). This was confirmed by siRNA-mediated Axl si-
lencing (Additional file 3: Figure S2). We further con-
firmed that BGB324 reduced phosphorylation of
extracellular signal-regulated kinase (ERK) and AKT in
PC9 cells and H1975 cells (Additional file 3: Figure S3).
A selective MEK inhibitor (U1206) or an allosteric AKT
inhibitor (MK-2206) decreased mRNA expression of
PD-L1 (Additional file 3: Figure S4), suggesting that ERK
and AKT were at least partly involved in downstream
signalling pathways of Axl [7].
Positive correlation of AXL expression with co-inhibitory
and co-stimulatory molecules across multiple cancers
So far, through the unbiased transcriptome analyses and
the subsequent in vitro cell culture assays, we identified a
new role of Axl kinase in up-regulating PD-L1 in lung
adenocarcinoma. We then sought to extend this finding to
several cancers including EGFR-related cancers (glioblast-
oma and colon cancer) and other solid tumors (melanoma,
renal cell carcinoma, gastric cancer and head and neck can-
cer), most of which Nivolumab have been approved for the
treatment. In addition we wished to clarify a broader ex-
pression pattern of co-inhibitory and co-stimulatory mole-
cules whose expressions correlated with Axl kinase. Using
TCGA datasets, we found that the EGFR-related cancers
exhibited more significant correlation of PD-L1 mRNA ex-
pression with AXL expression (Additional file 2: Table S6).
Moreover co-inhibitory receptors (PDCD1 encoding PD-1
and HAVCR2 encoding Tim3) and co-stimulatory receptors
(CD28 and CD137) showed the significant correlation with
AXL across a variety of cancers (Additional file 2: Table S6).
In summary, our findings suggest that Axl kinase
up-regulates several pathways such as immune checkpoint
molecules/chemokine signalling involved in regulation of
the immune microenvironment and tumor proliferation
(Additional file 3: Figure S5). Considering the diverse
non-genomic actions driven by Axl, monotherapies
targeting immune checkpoint molecules such as PD-L1 or
PD-L2/PD-1 or chemokines might not yield sufficient
treatment efficacy in patients with Axl-positive NSCLC.
This hypothesis is supported by a recent report demon-
strating that Axl was up-regulated in melanomas with in-
nate resistance to an anti-PD-1 therapy [8]. Given our
results, it might be possible that Axl kinase inhibition
could increase the sensitivity to a PD-1 targeted therapy.
In addition NSCLC harbouring EGFR mutations are asso-
ciated with poor efficacy of PD-1/PD-L1 inhibitors [9].
We therefore speculate that Axl kinase drives multiple
molecular pathways promoting tumor progression espe-
cially in EGFR-mutated lung adenocarcinoma.
There are some limitations in the present study. First
we did not observe correlation between Axl kinase and
these immune-related molecules at a protein level. Sec-
ond we have not tested if Axl kinase promotes immune
checkpoint molecules and chemokines that function in
in vivo settings. Third we cannot exclude a possibility
that PD-L1-bearing cell-types other than cancer cells
were involved in this bioinformatic analysis as we ana-
lyzed transcriptome data from whole tissue lysates but
not at a single cell level. Further validation studies using
immunohistochemistry, animal models and a single
cell-RNA sequence are required.
In conclusion, Axl-highly expressing lung adenocarcin-
omas exhibit higher expressions of multiple genes en-
coding immune checkpoint molecules and chemokines/
chemokine receptors. Our data therefore provide a ra-
tionale for further mechanistic studies to validate the
role of Axl kinase as a driver in diversifying downstream
molecules in NSCLC and, ultimately, to perform trials
testing the efficacy of Axl inhibition in the Axl-highly
expressing subset of NSCLC.
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